Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era

We evaluated the clinical significance of prognostic factors including the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma (MM) who underwent upfront single autologous stem cell tran...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2015-02, Vol.106 (2), p.179-185
Main Authors: Takamatsu, Hiroyuki, Honda, Sumihisa, Miyamoto, Toshihiro, Yokoyama, Kenji, Hagiwara, Shotaro, Ito, Toshiro, Tomita, Naoto, Iida, Shinsuke, Iwasaki, Toshihiro, Sakamaki, Hisashi, Suzuki, Ritsuro, Sunami, Kazutaka
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - therapeutic use
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autografts
Autologous stem cell transplantation
Blood
Chemotherapy
Female
Hematopoietic Stem Cell Transplantation - methods
Humans
Immunologic Factors - administration & dosage
immunomodulator drugs
International Staging System
Male
Medical prognosis
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - immunology
Multiple Myeloma - metabolism
Original
Patients
Prognosis
Proteasome inhibitors
Proteasome Inhibitors - administration & dosage
Retrospective Studies
Stem cell transplantation
Stem cells
Survival Rate
Transplantation, Autologous - methods
Transplants & implants
Urine
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the clinical significance of prognostic factors including the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma (MM) who underwent upfront single autologous stem cell transplantation (ASCT). We categorized patients into two treatment cohorts: pre‐novel agent era (1995–2006) and novel agent era (2008–2011). The combined percentage of pre‐ASCT complete response and very good partial response cases (463 of 988, 47%) significantly increased during the novel agent era compared with the pre‐novel agent era (164 of 527, 31%; P 
ISSN:1347-9032
1349-7006
DOI:10.1111/cas.12594